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Background: Activated PI3K-AKT pathway may contribute to decrease sensitivity to inhibitors of key pathogenetic
effectors (mutated BRAF, active NRAS or MEK) in melanoma. Functional alterations are deeply involved in PI3K-AKT
activation, with a minimal role reported for mutations in PIK3CA, the catalytic subunit of the PI3K gene. We here
assessed the prevalence of the coexistence of BRAF/NRAS and PIK3CA mutations in a series of melanoma samples.
Methods: A total of 245 tumor specimens (212 primary melanomas and 33 melanoma cell lines) was screened for
mutations in BRAF, NRAS, and PIK3CA genes by automated direct sequencing.
Results: Overall, 110 (44.9%) samples carried mutations in BRAF, 26 (10.6%) in NRAS, and 24 (9.8%) in PIK3CA. All
identified PIK3CA mutations have been reported to induce PI3K activation; those detected in cultured melanomas
were investigated for their interference with the antiproliferative activity of the BRAF-mutant inhibitor vemurafenib.
A reduced suppression in cell growth was observed in treated cells carrying both BRAF and PIK3CA mutations as
compared with those presenting a mutated BRAF only. Among the analysed melanomas, 12/245 (4.9%) samples
presented the coexistence of PIK3CA and BRAF/NRAS mutations.
Conclusions: Our study further suggests that PIK3CA mutations account for a small fraction of PI3K pathway
activation and have a limited impact in interfering with the BRAF/NRAS-driven growth in melanoma.
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Several cell-signaling pathways participate in develop-
ment and progression of melanoma. Among others, two
RAS-driven signal-transduction networks play a crucial
role in melanoma pathogenesis: the PI3K/AKT/mTOR
and, mainly, the BRAF/MEK/ERK pathways [1-3]. Activa-
tion of the latter one, also known as the mitogen-activated
protein kinase (MAPK) pathway, is mostly driven by onco-
genic mutations in BRAF and, to a less extent, in NRAS
genes; somatic mutations in such two genes are mutually
exclusive and able to stimulate cell proliferation and
tumor growth, through induction of a constitutive ERK
phosphorylation [1-3]. Different events may instead con-
tribute to activate the PI3K/AKT pathway: PI3K stimula-
tion by active GTP-bound RAS, occurrence of activating* Correspondence: gpalmieri@yahoo.com
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unless otherwise stated.mutations in PIK3CA (the catalytic subunit of the PI3K
gene), or silencing of the PTEN tumor suppressor gene
[4,5]. The intracellular accumulation of active AKT results
in enhancement of cell survival, migration capability, and
resistance to apoptosis in human cancers, including mel-
anoma [6,7].
At present, inhibitors of key effectors into the MAPK
pathway (BRAF-mutant inhibitors, as vemurafenib or
dabrafenib, MEK inhibitors, as trametinib, and their
combination) are allowing to overcome the ineffective-
ness of the conventional therapies [8]. In patients treated
with such inhibitors, a rapid acquisition of drug resist-
ance, as consequence of reactivation of the MAPK path-
way or activation of alternative signaling pathways, has
been reported to however limit the survival benefits
[9,10]. Nevertheless, a fraction of them are primarily re-
fractory due to an intrinsic resistance to such inhibitors
[9,10]. On this regard, an increasing amount of evidence
indicates that multiple mechanisms may contribute toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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those underlying intratumor heterogeneity, alterations in
tumor microenvironment (i.e. growth factors and cyto-
kines that interact with their corresponding receptors as
well as hormones and neuropeptides), and the ability of
tumor to generate an immunosuppressive environment
[3,8,11-13]. Even different levels of intralesional pigmen-
tation may interfere with melanoma pathogenesis and/or
affect the behavior of the disease [12,13].
At intracellular and molecular level, crosstalk mecha-
nisms between the MAPK and PI3K/AKT pathways,
with the mutated BRAF inducing a negative regulation
of the AKT network, have been described [14]. Inactiva-
tion of the oncogenic BRAF by targeted inhibitors is thus
supposed to increase the intracellular levels of phos-
phorylated AKT, contributing to the enhancement of cell
survival and the development of drug resistance [14].
Suppression of AKT activity by inhibition of either up-
stream (PI3K) or downstream (mTOR) effectors of this
signaling cascade is being proposed as an effective tool for
the improvement of the antitumor response to the
MAPK-targeted therapies [15-17]. In preclinical studies,
combined treatment based on inhibition of BRAF and
silencing of AKT3 was found to significantly increase
suppression of tumour growth as compared to the
result obtained by single agent administration [18,19].
Recently, combination of a BRAF or MEK inhibitor with
a PI3K/mTOR inhibitor was found to enhance cell
growth inhibition through achievement of ERK hypo-
phosphorylation, overcoming the resistance encoun-
tered by the use of a single anti-BRAF or anti-MEK
agent [17,20].
Overall, identification of melanomas with activated al-
ternative signaling pathways may be helpful in selecting
the fraction of patients carrying BRAFmutations primarily
refractory to the treatment with either a BRAF or MEK in-
hibitor. In our case, this raises the question whether a test
for detecting the activation of the PI3K/AKT pathway
should be routinely used in clinical practice for a more
accurate classification of the patients before addressing
them to be treated with such inhibitors.
Toward the identification of a more appropriate test
for assessing the activated status of the PI3K/AKT path-
way, genetic variations, whose assessment is qualitative
(detecting the objective presence or absence of each spe-
cific sequence variant), can be considered as more reliable
predictive markers as compared to expression alterations,
whose classification is quantitative or semi-quantitative
(for immunohistochemistry, strictly depending on subject-
ive evaluation of both intensity and distribution of tissue
protein staining). Since PTEN is mostly inactivated by
gene deletions or rearrangements [21] as well as AKT and
mTOR are mainly altered at functional level, PI3K - and,
particularly, its catalytic subunit PIK3CA - remains thegene mostly affected by activating somatic mutations into
this pathway [5].
The aim of this study was to investigate the preva-
lence and distribution of pathogenetic variants in BRAF,
NRAS, and PIK3CA genes among 245 DNA samples from
pigmented melanomas of cutaneous origin, defining the
fraction of cases harboring coexistent PIK3CA and BRAF
or NRAS mutations. Melanoma cell lines with coexist-
ence of PIK3CA and BRAF mutations were also investi-
gated to evaluate the level of interference with the




One hundred and eighty-six patients with histologically-
proven diagnosis of pigmented melanoma of cutaneous
origin were included into the study. After obtaining their
written consent for tissue sampling, patients were enrolled
consecutively between March 2010 and November 2012
from centers in Italy, regardless of cancer family history and
disease characteristics. Formalin-fixed, paraffin-embedded
primary melanoma tissues were obtained from pathological
archives for all patients; in 26 of them with multiple
primary melanoma, two synchronous or asynchronous
primary tumor tissues were collected. Synchronous mela-
nomas were diagnosed in four patients during the same
first observation or, at the most, within one month from
the first diagnosis, according to previously defined criteria
[22]. In the remaining 22 patients with asynchronous mul-
tiple melanomas, the subsequent primary tumors were
diagnosed at a median time from the first diagnosis of
28 months (range, 6–83 months). Vast majority (189/212;
89%) of primary melanomas included into the study were
from intermittently sun-exposed skin.
To improve sensitivity of nucleotide sequencing (se-
quence variants can be detected when the mutant alleles
are at least 15%-20% of the analyzed DNA sample), the
neoplastic portion of each tissue section was isolated in
order to obtain tumor samples with at least 80% neo-
plastic cells.
Mutation analysis
Genomic DNA was isolated from tumor tissues, using
standard methods. The coding sequence and splice junc-
tions of the mostly mutated domains of candidate genes
(exon 15 in BRAF, exons 2 to 4 in NRAS, and exons 9
and 20 in PIK3CA) were screened for mutations by dir-
ectly sequencing the amplified PCR products, using an
automated fluorescence-cycle sequencer (ABIPRISM 3130,
Life Technologies/ThermoFisher Scientific, Waltham, MA,
USA). Primer sequences were as previously-reported by
our group [23,24]. Sequencing analysis was conducted in
duplicate (two PCR assays from two different tumor
Table 1 Characteristics of analyzed patients and
melanomas
Characteristics No. %
Total patients analyzed 186
Males/Females 99/87 53/47
Median age (years) 51
Range 19-83






Total melanoma analyzed 212
Primary site




Superficial spreading 135 64
Nodular 77 36
AJCC, American Joint Committee on Cancer.
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all samples. A nucleotide sequence was considered as valid
when the quality value (QV) was higher than 20 (<1/100
error probability); in this study, the QV average was 40
(range, 30–45; <1/1000-1/10,000 error probability).
Melanoma cell lines and in vitro proliferation test
For in vitro proliferation assay, four melanoma cell lines
were selected: 13443-Mel (with BRAFwild-type and PIK3-
CAwild-type; as negative control), PNP-Mel (with
BRAFV600E and PIK3CAwild-type), M14 (with BRAFV600E
and PIK3CAP539R), and M259 (with BRAFV600E and
PIK3CAE545K). Cells were plated in triplicate in 96-well
plates, at a density of 3–5 × 103 per well, in fresh medium
(RPMI 1640; Invitrogen/ThermoFisher Scientific, USA)
only, as control, or medium containing different con-
centrations of vemurafenib (PLX4032, RG7204; Selleck
Chemicals, Houston, TX). In particular, melanoma cell
lines were treated in triplicate with increasing concentra-
tions (5 to 100 nM) of vemurafenib for 72 hrs. The
percentage of melanoma cell proliferation was esti-
mated on day 4 by a colorimetric assay, as we previously
described [25].
Statistical analysis
All in vitro data derive from at least three independent
experiments and results are expressed as mean values with
95% confidence intervals. The statistical significance of
differential findings between experimental and control
groups was determined by ANOVA with the Tukey’s
multiple comparison test in Graph-Pad Prism 3.0 soft-
ware (Graph-Pad Software, Inc., San Diego, CA, USA).
These findings were considered significant if two-tailed
P values were <0.05.
Results and discussion
A total of 245 tumor specimens (212 primary melano-
mas and 33 melanoma cell lines) was screened for muta-
tions in BRAF, NRAS, and PIK3CA genes. Tumor tissues
were collected from 186 patients, since 26 of them
presented two synchronous or asynchronous primary
melanomas (see Methods for details). Median age of the
enrolled patients was 51 years (range, 19–83 years); 99
(53%) were men. Patients’ characteristics are shown in
Table 1. For majority (18/33; 55%) of melanoma cell lines,
main genotypic features have been previously described
[26]; however, an extensive genetic and molecular analysis
of candidate genes among the entire series of cell lines is
being completed (Sini, manuscript in preparation).
Overall, 160 (65.3%) melanoma samples carried muta-
tions in at least one of such candidate genes: 110 (44.9%)
in BRAF, 26 (10.6%) in NRAS, and 24 (9.8%) in PIK3CA
(Table 1). For PIK3CA mutations, screening revealed the
occurrence of five mutations (p.P539R, p.E542K, p.E545A,p.E545G, and p.E545K in exon 9; no sequence variation
was detected in exon 20), which have been widely
reported in mutation databases [Human Gene Mutation
Database (HGMD) at http://www.hgmd.cf.ac.uk/ac/
all.php and Catalogue Of Somatic Mutations In Cancer
(COSMIC) at http://cancer.sanger.ac.uk/cancergenome/pro-
jects/cosmic/] as commonly associated with human cancer,
with a recognized functional role of the corresponding
mutated proteins. The variant p.E545A was the mutation
with the highest frequency in our series [detected in 14/24
(58.3%) PIK3CA mutants].
Among analyzed melanomas, 12/245 (4.9%) samples
presented the coexistence of PIK3CA and BRAF or
NRAS mutations [11 cases with BRAF and PIK3CA mu-
tations and 1 case with NRAS and PIK3CA mutations;
Table 2). On the other hand, NRAS or BRAF mutations
were found in half (12/24; 50%) of patients with PIK3CA
mutations, which were conversely detected in less than
one tenth (12/136; 8.8%) of cases with NRAS or BRAF
mutations (Table 2). Among the 212 tumor tissues of
our series, 52 samples were from 26 patients with mul-
tiple primary melanoma (all such cases presented two
synchronous or asynchronous primary melanomas). As
shown in Table 3, about half (12/26; 46.2%) of patients
with multiple melanoma showed discrepancies in muta-
tion patterns between first and subsequent primary tu-
mors, further supporting our previous observations that
molecular mechanisms underlying the development of
Table 2 Frequencies of somatic mutations in the three candidate genes
Sample
BRAF NRAS BRAF + PIK3CA NRAS + PIK3CA PIK3CA Wild-type
% % % % % %
Primary melanoma (N = 212)
81 21 9 1 10 90
38.2 9.9 4.2 0.5 4.7 42.5
Melanoma cell line (N = 33)
18 4 2 0 2 7
54.5 12.1 6.1 0 6.1 21.2
Total (N = 245)
99 25 11 1 12 97
40.4 10.2 4.5 0.4 4.9 39.6
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neous [27,28].
Using a panel of four melanoma cell lines carrying
constitutive differences in mutational status of both BRAF
and PIK3CA genes (including the only two cell lines with
coexistence of BRAF and PIK3CA mutations; see Table 2
and Methods), we have investigated the ability of the
BRAF-mutant inhibitor vemurafenib to halt cell prolifera-
tion. As expected, a remarkable anti-proliferative activity
by this drug was observed in the PNP-Mel cells (present-
ing a mutated BRAF and a wild-type PIK3CA), whereas
lack of a significant inhibitory effect on growth was dem-
onstrated in control cells carrying wild-type BRAF and
PIK3CA (Figure 1). Suppression in cell proliferation was
instead less evident or minimal on BRAF-mutated M14
(presenting the p.P539R mutation in PIK3CA) and M259
(with the p.E545K mutation in PIK3CA) cell lines, respect-
ively (Figure 1). Although experimental assays should be
carried extensively on a larger series of melanoma cell
lines, our findings permit to speculate that activatingTable 3 Consistency between BRAF/NRAS/PIK3CA mutations in
patterns in those in whom there were discrepancies
No. of
cases
Cases with consistent mutation patterns
















Abbreviation: wt wild-type.mutations of PIK3CA may interfere with the anti-
proliferative effects of BRAF inhibitors on melanomas
carrying oncogenic variants of BRAF (though levels of
interference may vary, strictly depending on the type of
sequence alterations at the functional domains of the
PIK3CA gene). Although our results are consistent with
data from literature - indicating that absence of an acti-
vated PI3K-AKT pathway may contribute to increase sen-
sitivity to drugs inhibiting the oncogenically-active MAPK
components (either mutated BRAF or MEK) [29-32], it is
to keep in mind that other molecular features (BRAF
amplification, BRAF splice variants, MEK1-2 mutations,
RTK/NRAS activation, PTEN inactivation, RB1 loss, etc.)
may be associated with the decreased sensitivity to BRAF
inhibitors [10,11,33].
In our study, prevalence of pathogenetic PIK3CA mu-
tations in cutaneous melanoma tissues (20/212; 9%) was
much higher than that (about 2%) reported in HGMD
and COSMIC databases for in vivo melanoma samples.
Considering a collection of about 1,000 melanoma samplesmultiple melanomas from same patients, and mutation
mong discrepant paired samples
NRAS PIK3CA
tumor First tumor Second tumor First tumor Second tumor
wt wt wt wt
wt wt wt E545A
wt Q61R E545A wt
wt wt wt wt
wt wt E545A wt
wt wt wt wt
wt wt wt E542K
wt wt wt wt
wt wt wt wt
Q61R wt wt wt
wt wt E545G wt
wt wt wt wt
Figure 1 Effects of vemurafenib on the growth of human melanoma cell lines. Four melanoma cell lines were cultured in presence of
various concentrations of vemurafenib for 72 hours and cell proliferation was estimated as described in Methods. Results are expressed as
percent of cell growth and represent the average (± standard deviation) of triplicate experiments. RPMI, cell cultures in fresh medium only, as
control. Cisplatinum (CIS) at concentration of 5 μM was used as cytotoxicity positive control.
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[34-38], mutation rates in PIK3CA gene were consistently
identical during melanoma progression - from primary
cutaneous melanomas (2.3%) to metastatic melanomas
(2.5%) and melanoma cell lines (2.5%). For in vitro melan-
oma samples from our series, frequency of PIK3CA muta-
tions (4/33 melanoma cell lines; 12%) was even higher
than that above reported (though BRAF/NRAS mutations
remained the most prominent genetic alterations, acting
as main drivers of proliferation in vast majority of cul-
tured melanomas). Conversely, the rate of coexistence of
PIK3CA and BRAF or NRAS mutations (about 5%) in our
series was lower than that previously described (20%; [4]).
Overall, our findings further confirm that PIK3CA is
rarely subject to somatic activation through genetic
alterations in melanoma. In other words, sequence varia-
tions in PIK3CA gene only account for a small fraction
of activations of the PI3K-AKT signaling pathway and
are thus expected to minimally interfere with the BRAF/
NRAS-driven growth. Conversely, activation of AKT, the
main downstream component of the PI3K pathway, is
mostly determined at functional level as consequence of an
increased activity of the upstream effectors (RAS activa-
tion, PTEN suppression), with again a minimal role played
by genetic alterations (activating mutations in AKT1 and
AKT3 genes have been reported in a limited number of
melanomas and melanoma cell lines) [14,30,39]. Although
it is becoming evident that multiple mechanisms may
contribute to AKT activation in melanoma, loss of PTEN -
reported in about 10% of melanoma tissues and 30% of
cultured melanoma cells [35-37] - is considered the major
mechanism for abrogating oncogene-induced senes-
cence in either BRAF or NRAS mutant cells through acti-
vation of the PI3K-AKT signaling pathway [6,9,40,41].
In our collection of 33 melanoma cell lines, loss of the
PTEN expression was found in eight (24%) of them by
immunocytochemistry (data not shown). For this reason,occurrence of PTEN inactivation should be mainly evalu-
ated in melanoma patients harboring activation of the
MAPK pathway and undergoing treatment with BRAF
and MEK-selective inhibitors in order to determine
whether these alterations may be associated with a dimin-
ished clinical benefit.
In very next future, more accurate molecular signa-
tures of cancer tissues will be achieved through the ad-
vancements of the technologies. Indeed, next-generation
sequencing (NGS) approaches are already being demon-
strated to better characterize molecular mechanisms
underlying resistance to targeted therapies [33,42]. As
consequence, more reliable molecular biomarkers might
be available for improving the accurateness of the pre-
diction of the treatment outcome among patients with
melanoma.
Conclusions
In our study, the presence of a limited but representative
fraction of cases with coexistence of somatic mutations
in PIK3CA and BRAF or NRAS genes seems to somehow
represent an indicator for including mutation analysis of
PIK3CA into the initial (prior-to-therapy) strategies for
molecular classification of melanoma patients. This could
allow to prospectively make correlations between the co-
existence of PIK3CA/BRAF/NRAS mutations and rates of
intrinsic resistance to BRAF or MEK inhibitors.
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